NASDAQ:NARI

Inari Medical Competitors

$113.64
+0.19 (+0.17 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$110.88
Now: $113.64
$113.97
50-Day Range
$90.30
MA: $107.84
$125.92
52-Week Range
$39.55
Now: $113.64
$127.42
Volume506,385 shs
Average Volume603,040 shs
Market Capitalization$5.54 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Inari Medical (NASDAQ:NARI) Vs. TFX, PODD, ABMD, NVCR, PEN, and HRC

Should you be buying NARI stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Inari Medical, including Teleflex (TFX), Insulet (PODD), Abiomed (ABMD), NovoCure (NVCR), Penumbra (PEN), and Hill-Rom (HRC).

Inari Medical (NASDAQ:NARI) and Teleflex (NYSE:TFX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Inari Medical and Teleflex, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inari Medical01502.83
Teleflex00813.11

Inari Medical presently has a consensus target price of $116.1667, suggesting a potential upside of 2.22%. Teleflex has a consensus target price of $453.4444, suggesting a potential upside of 6.17%. Given Teleflex's stronger consensus rating and higher probable upside, analysts clearly believe Teleflex is more favorable than Inari Medical.

Institutional & Insider Ownership

17.8% of Inari Medical shares are held by institutional investors. Comparatively, 89.8% of Teleflex shares are held by institutional investors. 2.2% of Teleflex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Inari Medical and Teleflex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inari MedicalN/AN/AN/A
Teleflex14.66%16.33%7.66%

Valuation & Earnings

This table compares Inari Medical and Teleflex's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inari MedicalN/AN/AN/AN/AN/A
Teleflex$2.60 billion7.69$461.47 million$11.1538.30

Teleflex has higher revenue and earnings than Inari Medical.

Summary

Teleflex beats Inari Medical on 10 of the 10 factors compared between the two stocks.

Inari Medical (NASDAQ:NARI) and Insulet (NASDAQ:PODD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares Inari Medical and Insulet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inari MedicalN/AN/AN/A
Insulet3.33%8.94%2.07%

Valuation and Earnings

This table compares Inari Medical and Insulet's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inari MedicalN/AN/AN/AN/AN/A
Insulet$738.20 million25.70$11.60 million$0.191,511.21

Insulet has higher revenue and earnings than Inari Medical.

Analyst Ratings

This is a summary of recent recommendations for Inari Medical and Insulet, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inari Medical01502.83
Insulet19702.35

Inari Medical currently has a consensus target price of $116.1667, suggesting a potential upside of 2.22%. Insulet has a consensus target price of $254.2353, suggesting a potential downside of 11.46%. Given Inari Medical's stronger consensus rating and higher probable upside, equities analysts plainly believe Inari Medical is more favorable than Insulet.

Institutional and Insider Ownership

17.8% of Inari Medical shares are held by institutional investors. 1.1% of Insulet shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Insulet beats Inari Medical on 6 of the 9 factors compared between the two stocks.

Inari Medical (NASDAQ:NARI) and Abiomed (NASDAQ:ABMD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares Inari Medical and Abiomed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inari MedicalN/AN/AN/A
Abiomed25.89%15.34%13.51%

Valuation and Earnings

This table compares Inari Medical and Abiomed's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inari MedicalN/AN/AN/AN/AN/A
Abiomed$840.88 million17.96$203.01 million$4.7470.42

Abiomed has higher revenue and earnings than Inari Medical.

Analyst Ratings

This is a summary of recent recommendations for Inari Medical and Abiomed, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inari Medical01502.83
Abiomed12202.20

Inari Medical currently has a consensus target price of $116.1667, suggesting a potential upside of 2.22%. Abiomed has a consensus target price of $348.3333, suggesting a potential upside of 4.35%. Given Abiomed's higher probable upside, analysts plainly believe Abiomed is more favorable than Inari Medical.

Institutional and Insider Ownership

17.8% of Inari Medical shares are held by institutional investors. Comparatively, 94.0% of Abiomed shares are held by institutional investors. 3.4% of Abiomed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Abiomed beats Inari Medical on 7 of the 9 factors compared between the two stocks.

Inari Medical (NASDAQ:NARI) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares Inari Medical and NovoCure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inari MedicalN/AN/AN/A
NovoCure4.26%7.40%3.94%

Valuation and Earnings

This table compares Inari Medical and NovoCure's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inari MedicalN/AN/AN/AN/AN/A
NovoCure$351.32 million38.51$-7,230,000.00($0.07)-1,887.00

Inari Medical has higher earnings, but lower revenue than NovoCure.

Analyst Ratings

This is a summary of recent recommendations for Inari Medical and NovoCure, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inari Medical01502.83
NovoCure14402.33

Inari Medical currently has a consensus target price of $116.1667, suggesting a potential upside of 2.22%. NovoCure has a consensus target price of $139.2857, suggesting a potential upside of 5.45%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than Inari Medical.

Institutional and Insider Ownership

17.8% of Inari Medical shares are held by institutional investors. Comparatively, 71.1% of NovoCure shares are held by institutional investors. 5.1% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

NovoCure beats Inari Medical on 7 of the 9 factors compared between the two stocks.

Inari Medical (NASDAQ:NARI) and Penumbra (NYSE:PEN) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares Inari Medical and Penumbra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inari MedicalN/AN/AN/A
Penumbra-1.79%-0.12%-0.09%

Valuation and Earnings

This table compares Inari Medical and Penumbra's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inari MedicalN/AN/AN/AN/AN/A
Penumbra$547.41 million18.11$48.46 million$0.98277.58

Penumbra has higher revenue and earnings than Inari Medical.

Analyst Ratings

This is a summary of recent recommendations for Inari Medical and Penumbra, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inari Medical01502.83
Penumbra02402.67

Inari Medical currently has a consensus target price of $116.1667, suggesting a potential upside of 2.22%. Penumbra has a consensus target price of $279.00, suggesting a potential upside of 2.56%. Given Penumbra's higher probable upside, analysts plainly believe Penumbra is more favorable than Inari Medical.

Institutional and Insider Ownership

17.8% of Inari Medical shares are held by institutional investors. Comparatively, 88.2% of Penumbra shares are held by institutional investors. 8.9% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Inari Medical beats Penumbra on 5 of the 9 factors compared between the two stocks.

Inari Medical (NASDAQ:NARI) and Hill-Rom (NYSE:HRC) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares Inari Medical and Hill-Rom's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inari MedicalN/AN/AN/A
Hill-Rom7.74%22.71%8.01%

Valuation and Earnings

This table compares Inari Medical and Hill-Rom's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inari MedicalN/AN/AN/AN/AN/A
Hill-Rom$2.88 billion2.60$223 million$5.5320.42

Hill-Rom has higher revenue and earnings than Inari Medical.

Analyst Ratings

This is a summary of recent recommendations for Inari Medical and Hill-Rom, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inari Medical01502.83
Hill-Rom01602.86

Inari Medical currently has a consensus target price of $116.1667, suggesting a potential upside of 2.22%. Hill-Rom has a consensus target price of $121.00, suggesting a potential upside of 7.14%. Given Hill-Rom's stronger consensus rating and higher probable upside, analysts plainly believe Hill-Rom is more favorable than Inari Medical.

Institutional and Insider Ownership

17.8% of Inari Medical shares are held by institutional investors. Comparatively, 83.8% of Hill-Rom shares are held by institutional investors. 0.7% of Hill-Rom shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Hill-Rom beats Inari Medical on 9 of the 9 factors compared between the two stocks.


Inari Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Teleflex logo
TFX
Teleflex
1.8$427.09+1.6%$19.97 billion$2.60 billion54.97
Insulet logo
PODD
Insulet
1.4$287.13+0.9%$18.97 billion$738.20 million652.58
Abiomed logo
ABMD
Abiomed
1.4$333.81+1.2%$15.10 billion$840.88 million73.36
NovoCure logo
NVCR
NovoCure
1.5$132.09+0.3%$13.53 billion$351.32 million695.25Analyst Upgrade
Insider Selling
Penumbra logo
PEN
Penumbra
1.5$272.03+0.0%$9.92 billion$547.41 million-1,007.52
Hill-Rom logo
HRC
Hill-Rom
1.8$112.94+1.4%$7.49 billion$2.88 billion34.02
Globus Medical logo
GMED
Globus Medical
1.4$67.00+1.1%$6.69 billion$785.37 million72.83News Coverage
Haemonetics logo
HAE
Haemonetics
1.6$117.06+2.8%$5.95 billion$988.48 million56.55
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.2$218.45+3.3%$5.93 billion$82.05 million-94.16
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$70.12+0.9%$5.92 billion$1.52 billion104.66
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.6$87.99+0.0%$5.50 billion$362.30 million-108.63
Nevro logo
NVRO
Nevro
1.2$147.08+0.9%$5.09 billion$390.26 million-54.07
ShockWave Medical logo
SWAV
ShockWave Medical
1.2$137.01+0.7%$4.77 billion$42.93 million-67.83
ICU Medical logo
ICUI
ICU Medical
1.5$204.19+0.1%$4.33 billion$1.27 billion54.02
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.6$132.76+1.3%$3.87 billion$214.55 million-69.51
Glaukos logo
GKOS
Glaukos
0.9$83.13+3.3%$3.81 billion$236.98 million-50.38Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
Cantel Medical logo
CMD
Cantel Medical
1.3$83.76+0.5%$3.54 billion$1.02 billion99.72Insider Selling
NuVasive logo
NUVA
NuVasive
1.1$68.71+1.7%$3.53 billion$1.17 billion-312.32
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.50+1.5%$3.42 billion$994.85 million-116.04News Coverage
AtriCure logo
ATRC
AtriCure
1.5$65.90+1.0%$3.00 billion$230.81 million-57.30
Axonics Modulation Technologies logo
AXNX
Axonics Modulation Technologies
1.3$60.13+0.2%$2.50 billion$13.82 million-30.68
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$8.72+0.9%$1.82 billion$4.11 million-6.41
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99+0.2%$1.75 billion$88.02 million-58.51
Silk Road Medical logo
SILK
Silk Road Medical
1.1$50.14+0.7%$1.72 billion$63.35 million-41.10
Alphatec logo
ATEC
Alphatec
0.8$17.60+1.3%$1.67 billion$113.43 million-16.00Analyst Report
News Coverage
Luminex logo
LMNX
Luminex
1.8$32.95+2.0%$1.56 billion$334.64 million84.49News Coverage
Gap Up
Pulmonx logo
LUNG
Pulmonx
1.4$43.48+4.7%$1.55 billion$32.60 million0.00Insider Selling
Gap Down
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.13+0.8%$1.45 billion$236.54 million-54.74
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.72+5.0%$1.42 billion$299.26 million-13.53Gap Up
Atrion logo
ATRI
Atrion
1.1$644.00+0.3%$1.18 billion$155.07 million36.28
SI-BONE logo
SIBN
SI-BONE
1.2$33.76+0.5%$1.10 billion$67.30 million-21.10Insider Selling
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$54.00+0.9%$1.06 billion$189.49 million-120.00News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$51.44+2.0%$1.06 billion$117.23 million55.31
Cerus logo
CERS
Cerus
1.7$6.13+1.0%$1.03 billion$74.65 million-15.72Analyst Upgrade
Analyst Revision
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.55+0.0%$974.05 million$72.55 million-34.41Analyst Report
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.77+1.7%$906.52 million$264.16 million-5.32
CryoLife logo
CRY
CryoLife
2.0$22.61+0.1%$884.50 million$276.22 million-59.50
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.87+1.6%$836.48 million$459.95 million35.73
Surmodics logo
SRDX
Surmodics
1.3$57.14+0.9%$786.02 million$94.86 million714.25
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.42+0.3%$749.68 million$154.60 million-45.30
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.10+0.5%$689.46 million$123.86 million68.34Analyst Upgrade
Intersect ENT logo
XENT
Intersect ENT
1.4$20.49+1.7%$676.50 million$109.14 million-10.73News Coverage
SeaSpine logo
SPNE
SeaSpine
1.3$21.94+2.1%$612.85 million$159.08 million-13.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Vapotherm logo
VAPO
Vapotherm
1.5$23.26+0.7%$600.27 million$48.10 million-11.08News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$39.80+1.7%$570.33 million$114.51 million-84.68News Coverage
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.81+1.0%$568.96 millionN/A-9.61Analyst Downgrade
News Coverage
PAVmed logo
PAVM
PAVmed
1.2$6.00+1.8%$494.77 millionN/A-7.89
Accuray logo
ARAY
Accuray
2.3$5.21+0.6%$484.00 million$382.93 million37.21
iCAD logo
ICAD
iCAD
1.5$18.55+1.0%$462.23 million$31.34 million-19.53Analyst Upgrade
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$22.12+1.9%$457.29 million$11.22 million-50.27Gap Down
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.